ABCA1 | ATP-binding cassette, sub-family A (ABC1), member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ACE | Angiotensin I converting enzyme | Candidate cardiovascular disease genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACHE | Acetylcholinesterase (Yt blood group) | Blood group antigen proteins Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ATP1A1 | ATPase, Na+/K+ transporting, alpha 1 polypeptide | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
ATP2C1 | ATPase, Ca++ transporting, type 2C, member 1 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
BCL2 | B-cell CLL/lymphoma 2 | Cancer-related genes Disease related genes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD33 | CD33 molecule | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD4 | CD4 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD86 | CD86 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CYP19A1 | Cytochrome P450, family 19, subfamily A, polypeptide 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Expressed in all |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EDNRB | Endothelin receptor type B | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
EPHA2 | EPH receptor A2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FCER1G | Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |